Big Pharma and the antitrust bar both have a lot at stake as the Supreme Court considers what to do about "pay for delay" deals that keep generic drugs off the market. In the meantime, Lefkowitz won a ruling on pay-for-delay that gives the pharmaceutical industry some crucial breathing room where it needed it most, in the Third Circuit.

ARGUED OCTOBER 23, 2008 & MAY 27, 2010Before BAUER, WOOD, and TINDER, Circuit Judges.The two cases that we have consolidated for decision in this opinion both deal with the responsibilities